Spinal tap needle type impacts the risk of complications

December 06, 2017

Hamilton, ON (December 6, 2017) - The type of needle used during a lumbar puncture makes a significant difference in the subsequent occurrence of headache, nerve irritation and hearing disturbance in patients, according to a study by Hamilton medical researchers.

As well, they found the pencil-point atraumatic needle with the better tip design has been available for about 70 years, but few physicians have been using it because they have not been aware of its benefits over the conventional bevelled traumatic needles.

The implications on clinical care are huge, says Dr. Saleh Almenawer, the senior author of the study and a neurosurgeon at Hamilton Health Sciences who worked with a team of researchers at McMaster University.

"There is a more than 50 per cent reduction in the occurrence of headaches with the atraumatic needles, and also more than a 50 per cent reduction in patient readmissions and return to emergency rooms for narcotics or blood patches."

A lumbar puncture, commonly known as a spinal tap, is a regular medical procedure used to diagnose and to treat disease. Post-dural puncture headaches appear in about 35 per cent of patients, sometimes causing debilitating pain that can lead to a return to hospital for painkillers or more invasive treatment.

The study published today in The Lancet says using atraumatic needles rather than conventional traumatic needles for lumbar punctures is just as effective and results in a significant decrease in complications such as the headaches.

"The two needles differ in how they penetrate the thick membrane, called the dura, surrounding the nerves," said Almenawer.

He explained that the sharp edges of the tip of a conventional needle cuts its way through, while the tip of an atraumatic needle causes the tissue to dilate and contract around it. The tiny hole left in the dura by the atraumatic needle makes it significantly more difficult for cerebrospinal fluid to leak through, thus diminishing the frequency of headaches, readmissions and treatment.

The study pooled data from 110 clinical trials, with more than 30,000 participants in 29 countries across the past 28 years.

Atraumatic needles have been around for decades, but their use remains significantly limited, according to the researchers. They also found the atraumatic needles cost the same or up to three times as much as the more conventional type.

"Several surveys from around the world showed that only a fraction of physicians know atraumatic needles exist, and among those even a smaller portion use the atraumatic type," said Almenawer.

"Lumbar puncture is a standard procedure, with thousands done every day around the globe by physicians of many specialties. Unfortunately, conventional needles created in 1890 are still the default in most hospitals around the world. This study provides convincing high-quality evidence for people to change to the atraumatic needles for a better patient care."

An accompanying commentary on the research in The Lancet says the study points out "the practice needs to change".

"Clinicians should start using atraumatic needles for lumbar punctures. We need to change practice," said Diederik van de Beek and Matthijs Brouwer, two neurology professors of the University of Amsterdam.
-end-
There was no external funding for the study.

Editors: A photo of Dr. Saleh Almenawer and his research team is attached. Alex Koziarz, Saleh Almenawer, Sheila Singh and Siddharth Nath, left to right, led a study on lumbar puncture needles published in The Lancet. Photo courtesy McMaster University

Also is attached is a photo of the two needles used in lumbar puncture: Left: Conventional. Right: Atraumatic. Photo courtesy McMaster University

The post embargo link to the paper is: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32451-0/fulltext?elsca1=tlxpr

For more information:

Veronica McGuire
Media Relations
Faculty of Health Sciences
McMaster University
vmcguir@mcmaster.ca
905-525-9140, ext. 22169

McMaster University

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.